✦ LIBER ✦

Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension

✍ Scribed by Eric Crombez; Priya Kishnani; Hadhami Ben Turkia; Derlis Gonzalez; Ari Zimran; Madhulika Kabra; Elena Lukina; Pilar Giraldo; Isaac Kisinovsky; Ashish Bavdekar; Marie-Françoise Ben Dridi; Neerja Gupta

Book ID: 116989530
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 67 KB
Volume: 105
Category: Article
ISSN: 1096-7192
DOI: 10.1016/j.ymgme.2011.11.044

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of Velaglucerase Alf

Safety and Efficacy of Velaglucerase Alfa in Patients with Type 1 Gaucher Disease: 2 Years of Treatment in Phase III Trials and an Extension Study

✍ Ari Zimran; Madhulika Kabra; Pilar Giraldo; Marie-Françoise Ben Dridi; Deborah E 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Safety and efficacy of long-term enzyme

Safety and efficacy of long-term enzyme replacement therapy with velaglucerase alfa in patients with type 1 Gaucher disease transitioned from imiglucerase

✍ Elstein, Deborah; Giraldo, Pilar; Mehta, Atul; Pastores, Gregory; Rhead, William 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 367 KB

Safety and efficacy of long-term velaglu

Safety and efficacy of long-term velaglucerase alfa therapy in treatment-naïve adults with type 1 Gaucher disease: results from Phase III trials

✍ Giraldo, Pilar; Zimran, Ari; Mehta, Atul; Hughes, Derralynn; Hangartner, Thomas 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 265 KB